# ABUS — Arbutus Biopharma Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ABUS  
**Sources:** 14  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-abus-arbutus-biopharma-corp-catalysts-narrative-risks-5804

---

## Overview

Arbutus Biopharma Corp. (Nasdaq: ABUS) is a clinical-stage, virology-focused biopharmaceutical company headquartered in Warminster, Pennsylvania, pursuing a functional chronic hepatitis B (cHBV) cure and developing an oral PD-L1 inhibitor (AB-101) [[6]](https://www.marketscreener.com/news/tranche-update-on-arbutus-biopharma-corporation-s-equity-buyback-plan-announced-on-august-21-2026-ce785ad3d181ff23), [[12]](https://www.arbutusbio.com/), [[13]](https://www.arbutusbio.com/pipeline/). The following reflects the situation as of October 3, 2026. Note that one calendar item—the November 16, 2026 earnings release—comes from our own unverified tracking and should be treated as a lead to confirm [Calendar].

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-abus-arbutus-biopharma-corp-catalysts-narrative-risks-5804 (free to sign up)._
